Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$3.22
-2.1%
$3.24
$3.04
$18.00
$4.35M0.73105,261 shs4,700 shs
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
$2.38
$2.07
$10.85
$61.05MN/A171,558 shs43,600 shs
IntelGenx Technologies Corp. stock logo
IGXT
IntelGenx Technologies
$0.17
$0.17
$0.09
$0.22
$29.17M2.47N/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
$0.30
-3.3%
$0.82
$0.25
$4.71
$4.41M1.571.90 million shs2.44 million shs
Q Biomed Inc. stock logo
QBIO
Q Biomed
$0.00
$0.00
$0.00
$0.03
N/A2.224,600 shs14,151 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
0.00%0.00%0.00%0.00%-67.91%
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
0.00%0.00%0.00%0.00%0.00%
IntelGenx Technologies Corp. stock logo
IGXT
IntelGenx Technologies
0.00%0.00%0.00%0.00%0.00%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
0.00%+16.93%-65.18%-67.81%-91.13%
Q Biomed Inc. stock logo
QBIO
Q Biomed
0.00%0.00%0.00%-50.00%+∞
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/AN/AN/AN/AN/AN/AN/AN/A
IntelGenx Technologies Corp. stock logo
IGXT
IntelGenx Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
3.2776 of 5 stars
3.52.00.00.04.01.71.3
Q Biomed Inc. stock logo
QBIO
Q Biomed
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
0.00
N/AN/AN/A
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
0.00
N/AN/AN/A
IntelGenx Technologies Corp. stock logo
IGXT
IntelGenx Technologies
0.00
N/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
3.00
Buy$4.001,224.94% Upside
Q Biomed Inc. stock logo
QBIO
Q Biomed
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest QBIO, IGXT, HTBX, MBRX, and GHSI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
6/9/2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$4.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$12.25M0.35$0.14 per share23.15$6.39 per share0.50
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/AN/AN/AN/AN/AN/A
IntelGenx Technologies Corp. stock logo
IGXT
IntelGenx Technologies
$1.04M28.05N/AN/A($0.07) per share-2.39
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/A$1.77 per shareN/A
Q Biomed Inc. stock logo
QBIO
Q Biomed
$280KN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$160K$4.870.66N/A22.79%-73.69%-48.17%N/A
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/AN/A0.00N/AN/AN/AN/AN/AN/A
IntelGenx Technologies Corp. stock logo
IGXT
IntelGenx Technologies
-$9.93M-$0.06N/AN/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$21.76MN/A0.00N/AN/AN/A-278.80%-100.11%8/4/2025 (Estimated)
Q Biomed Inc. stock logo
QBIO
Q Biomed
-$2.05MN/A0.00N/AN/AN/AN/AN/A

Latest QBIO, IGXT, HTBX, MBRX, and GHSI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$0.71-$0.69+$0.02-$0.69N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$5.00155.28%N/A102.67%N/A
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/AN/AN/AN/AN/A
IntelGenx Technologies Corp. stock logo
IGXT
IntelGenx Technologies
N/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/AN/A
Q Biomed Inc. stock logo
QBIO
Q Biomed
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/A
16.68
16.59
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/AN/AN/A
IntelGenx Technologies Corp. stock logo
IGXT
IntelGenx Technologies
N/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/A
1.35
1.35
Q Biomed Inc. stock logo
QBIO
Q Biomed
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
20.21%
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
N/A
IntelGenx Technologies Corp. stock logo
IGXT
IntelGenx Technologies
N/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
15.52%
Q Biomed Inc. stock logo
QBIO
Q Biomed
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
101.35 million1.33 millionNot Optionable
Heat Biologics, Inc. stock logo
HTBX
Heat Biologics
4925.65 millionN/AOptionable
IntelGenx Technologies Corp. stock logo
IGXT
IntelGenx Technologies
38174.66 million101.21 millionNot Optionable
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
2014.13 million13.86 millionNot Optionable
Q Biomed Inc. stock logo
QBIO
Q Biomed
3N/AN/ANot Optionable

Recent News About These Companies

Q BioMed Inc
Orchestra Biomed Reports Q3 2024 Financial Results
A Powerful New Tool for Biomedical Research
Q BioMed Inc QBIO
Biomedical Sciences PhD Program
QBIO Q BioMed Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Guardion Health Sciences stock logo

Guardion Health Sciences NASDAQ:GHSI

Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.

Heat Biologics stock logo

Heat Biologics NASDAQ:HTBX

Heat Biologics, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. Heat Biologics, Inc. has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.

IntelGenx Technologies stock logo

IntelGenx Technologies OTCMKTS:IGXT

$0.17 0.00 (0.00%)
As of 05/27/2025

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

Moleculin Biotech stock logo

Moleculin Biotech NASDAQ:MBRX

$0.30 -0.01 (-3.30%)
As of 04:00 PM Eastern

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Q Biomed stock logo

Q Biomed OTCMKTS:QBIO

$0.0001 0.00 (0.00%)
As of 09:57 AM Eastern

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.